dexpropranolol has been researched along with propafenone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pajeva, IK; Wiese, M | 1 |
| Bischoff-Kont, I; Chaikuad, A; Faudone, G; Fürst, R; Heering, J; Kaiser, A; Knapp, S; Merk, D; Rachor, L; Willems, S; Zhubi, R | 1 |
2 other study(ies) available for dexpropranolol and propafenone
| Article | Year |
|---|---|
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
Topics: Adenosine Triphosphatases; Algorithms; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Binding, Competitive; Caco-2 Cells; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoresceins; Humans; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Radioligand Assay; Rhodamine 123; Stereoisomerism; Verapamil; Vinblastine | 2002 |
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioblastoma; HEK293 Cells; Humans; Molecular Structure; Orphan Nuclear Receptors; Propranolol; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship | 2021 |